Tirzepatide associated with greater weight loss in women than men
All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced… read more.
All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced… read more.
Treatment with semaglutide and tirzepatide led to significant weight loss and improved blood sugar control in overweight or obese patients with type 1 diabetes (T1D). Researchers reported this… read more.
The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took… read more.
Detailed results from SURMOUNT-4, which showed Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related… read more.
The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine… read more.
Eli Lilly’s Mounjaro is recommended for use in Europe for the treatment of obesity. The recommendation comes the same week the drug was approved for obesity treatment in… read more.
The FDA approved Eli Lilly and Company’s Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1… read more.
A phase 3 clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were… read more.
Tirzepatide. a once weekly GIP and GLP-1 receptor agonist, treats early-onset type 2 diabetes as effectively as it treats type 2 diabetes diagnosed later in life, researchers reported… read more.